Undisclosed EP300 protein degrader / Foghorn Therap - LARVOL DELTA

Selective EP300 degrader program. (Investing News Network (INN)) - "IND targeted in 2027, with a focus in MM and DLBCL."

IND • Diffuse Large B Cell Lymphoma • Multiple Myeloma

Selective EP300 degrader program. (Foghorn Press Release) - "New preclinical data...for our Selective EP300 degraders highlight the therapeutic potential in multiple myeloma including superior anti-tumor activity with complete responses...IND-enabling studies anticipated in 2026 with expected IND in 2027."

Preclinical • Multiple Myeloma

Leveraging selective degradation of CBP and EP300 for potent anti-cancer activity (AACR 2026) - "Additionally, we demonstrate that CBP and EP300 selective degraders show strong anti-proliferative effects across numerous oncology indications that are dependent on either target. Importantly, treatment with our selective degraders at efficacious doses is not associated with hematopoietic toxicity, providing evidence that specific targeting of one of the paralogs provides a wider therapeutic window than dual inhibition."

Colorectal Cancer • Hematological Malignancies • Oncology • CREBBP • EP300

Title: Targeting chromatin regulatory proteins in hematologic malignancies (GlobeNewswire) - "Foghorn Therapeutics presents new preclinical data...at the 2026 AACR Annual Meeting....Targeting EP300 represents a well-validated example of lineage dependence in hematologic malignancies. In preclinical multiple myeloma studies, selective EP300 degraders show: Tumor regression, including a model with acquired resistance to pomalidomide with superior efficacy to clinical benchmark dual CBP/EP300 inhibitor inobrodib; A profound impact on multiple transcription factors important for the survival of multiple myeloma cells; Synergistic impact on cancer cells in the context of combinations with several standards of care."

Preclinical • Multiple Myeloma

Title: Preclinical evaluation of selective and potent EP300 degraders demonstrates robust antitumor activity and favorable tolerability in hematologic malignancies (GlobeNewswire) - "Foghorn Therapeutics presents new preclinical data...at the 2026 AACR Annual Meeting....Foghorn’s Selective EP300 degraders demonstrate promise for the treatment of hematological malignancies with preclinical data showing: Superior anti-tumor activity, including complete responses, compared to clinical benchmark dual CBP/EP300 inhibitor inobrodib...; Tumor regression in a multiple myeloma xenograft model of acquired pomalidomide resistance; Selective EP300 degradation as a novel and promising therapeutic strategy to treat multiple myeloma."

Preclinical • Multiple Myeloma

Program Overview and Upcoming Milestones:…Selective EP300 degrader program (GlobeNewswire) - "Preclinical efficacy and safety data for selective EP300 degraders in models of hematological malignancies demonstrate broad anti-tumor activity across more than 70% of hematologic sub-lineages tested, highlighting the program’s wide therapeutic potential. A VHL-based selective degrader has shown impressive efficacy in MM without hematologic toxicities, including thrombocytopenia, and EP300 degraders have retained full efficacy in IMiD-resistant multiple myeloma cell lines....Selective EP300 degrader program tracking to IND-enabling studies in 2026 with a focus in multiple myeloma (MM) and diffuse large b-cell lymphoma (DLBCL)."

Preclinical • Diffuse Large B Cell Lymphoma • Multiple Myeloma

Phase 1 dose-escalation trial of FHD-909 (LY4050784) advancing as planned, targeting SMARCA4 (BRG1)-mutant cancers with a focus on non-small cell lung cancer (NSCLC) (GlobeNewswire) - "Selective CBP degrader program with potential in ER+ breast cancer on track to be IND-ready in 2026; Selective EP300 degrader program shows preclinical superior anti-tumor efficacy and tolerability over dual CBP/EP300; EP300 degrader program – IND-enabling studies expected in 2026, with a focus in MM and DLBCL....Pending successful Phase 1 dose escalation results, Foghorn and Lilly anticipate evaluating FHD-909 in combination studies in the front-line setting of NSCLC."

IND • Preclinical • Trial status • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Multiple Myeloma • Non Small Cell Lung Cancer

Foghorn is advancing a Selective EP300 degrader program, with an initial focus in MM and DLBCL, on track for IND-enabling studies in 2026. Key updates include: (Foghorn Press Release) - "Broad anti-tumor activity in over 70% of all heme sub-lineages tested; VHL based selective degrader shows efficacy in MM without hematological toxicities, including thrombocytopenia; EP300 degraders show efficacy in IMiD-resistant MM cell lines; Tolerability profile with widespread potential for combinations"

Preclinical • Multiple Myeloma

Program Overview and Upcoming Milestones (GlobeNewswire) - "Continued progress on Selective EP300 degrader and Selective ARID1B degrader, with program updates expected in Q4 2025...Selective CBP degrader program....On track for IND-enabling studies, targeting an IND in 2026."

IND • Preclinical • Diffuse Large B Cell Lymphoma • Estrogen Receptor Positive Breast Cancer • Hematological Malignancies • Multiple Myeloma • Solid Tumor

Foghorn Therapeutics Provides First Quarter 2025 Financial and Corporate Update (GlobeNewswire) - "Selective CBP degrader on track for IND-enabling studies, targeting IND in 2026; Continued progress on Selective EP300 degrader and Selective ARID1B degrader with program updates expected in H2 2025."

IND • Preclinical • Oncology

Poster Title: Anti-cancer Activity of Potent and Selective EP300 Degradation in Hematological Malignancies (Presentation on Wednesday April 30, 2025) (GlobeNewswire) - "Foghorn Therapeutics...announced new preclinical data for potential first-in-class medicines...at the 2025 American Association for Cancer Research (AACR) Annual Meeting....Anti-proliferative activity in a broad range of hematological malignancies in vitro, including DLBCL, multiple myeloma, and follicular lymphoma. Achieved in vivo efficacy in the Karpas422 germinal center B-cell-like (GCB)-DLBCL xenograft model. No thrombocytopenia observed in mice at efficacious doses."

Preclinical • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Multiple Myeloma

Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting (GlobeNewswire) - "Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target population; Additional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignancies."

Preclinical • Non Small Cell Lung Cancer

Foghorn Therapeutics Announces New Preclinical Data for Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and EP300 Degrader Programs at 2025 AACR Meeting (GlobeNewswire) - "Poster presentations on the Phase 1 trial design for FHD-909 and on preclinical data for the Selective CBP program and the Selective EP300 degrader program will also be presented."

Clinical protocol • Preclinical • Hematological Malignancies • Solid Tumor

Foghorn Therapeutics Provides Financial Update for 2024 and 2025 Strategic Outlook (GlobeNewswire) - "Ongoing first-in-human Phase 1a/b open-label, multicenter trial design for FHD-909 will be presented at the AACR Annual Meeting (April 25-30, 2025)...In 2025, preclinical data for the Selective CBP degrader program, in combination with approved chemotherapeutics and targeted agents, will be presented at the AACR Annual Meeting (April 25-30, 2025)...In 2025, preclinical data for the Selective EP300 degrader program demonstrating biological activity in hematological malignancies will be presented at the AACR Annual Meeting (April 25-30, 2025)."

P1 data • Preclinical • Bladder Cancer • Endometrial Cancer • Gastric Cancer • Hematological Malignancies • Prostate Cancer • Solid Tumor

Foghorn Therapeutics Highlights Program Progress and Strategic Objectives for 2025 (GlobeNewswire) - "Selective EP300 degrader program: Identified potent and selective EP300 degraders and advancing oral degrader efforts. Pharmacodynamic and pharmacokinetic preclinical data demonstrate candidates: Are well tolerated in vivo with no observed decrease in platelet levels, and no effects on megakaryocyte viability at pharmacologically relevant concentrations in ex vivo studies; Have robust anti-tumor activity in solid tumors and hematological malignancies, including prostate cancer, multiple myeloma, and diffuse large B cell lymphoma."

Preclinical • Diffuse Large B Cell Lymphoma • Genito-urinary Cancer • Multiple Myeloma • Prostate Cancer • Solid Tumor

Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs (GlobeNewswire) - "Poster 6064 / 23: Discovery of potent and selective EP300 degraders with anti-cancer activity Preclinical pharmacodynamic and pharmacokinetic data presented at AACR support the identification of potent and selective EP300 degraders with anti-tumor activity in prostate and hematological malignancies: Reduced growth of androgen receptor positive prostate cells and attenuated androgen signaling; Reduced the growth of prostate cancer xenograft tumors in mice; Broad anti-tumor activity across a panel of multiple myeloma and DLBCL cell lines; In vivo efficacy demonstrated in a DLBCL model."

Preclinical • Diffuse Large B Cell Lymphoma • Multiple Myeloma • Prostate Cancer

Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook (GlobeNewswire) - "Foghorn is presenting new preclinical data for its CBP and EP300 selective degrader programs at the 2024 AACR Annual Meeting...CBP selective degraders have shown significant tumor growth inhibition in a colorectal cancer in vivo model. Antiproliferative effects were also observed for numerous cancer cell lines, including colorectal, gastric and bladder cancers; EP300 selective degraders have shown potent cellular antiproliferation and in vivo tumor growth inhibition in an AR+ enzalutamide prostate in vivo model."

Preclinical • Colorectal Cancer • Prostate Cancer • Solid Tumor

Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 (GlobeNewswire) - "Poster presentation of FHD-909, a first-in-class oral BRM selective inhibitor, highlighting preclinical efficacy and safety in multiple mouse models of NSCLC....IND filing planned in Q2 2024; Oral presentation demonstrating preclinical efficacy and tolerability data for Selective CBP and Selective EP300 degraders; Significant anti-tumor activity observed, with no thrombocytopenia as historically observed with dual CBP/EP300 inhibitors; Additional poster presentation demonstrating long-acting degrader capabilities confirming up to once-a-month dosing for protein degrader programs."

IND • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 (GlobeNewswire) - "Selective EP300 and Selective CBP programs: At preclinical efficacious doses, neither the EP300 nor the CBP selective degraders caused thrombocytopenia, a commonly observed safety liability for dual CBP/EP300 inhibitors. Additional preclinical data will be presented in the first half of 2024."

Preclinical • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs (GlobeNewswire) - "Foghorn® Therapeutics Inc...today announced that the Company will present new data from multiple preclinical and clinical programs at the 6th Annual Targeted Protein Degradation (TPD) Summit and the Connective Tissue Oncology Society (CTOS) Annual Meeting....Foghorn will participate in multiple sessions, including a keynote presentation by Steve Bellon, Foghorn’s Chief Scientific Officer, where data from its selective EP300 and CBP degrader programs will be presented."

Clinical data • Preclinical • Oncology

Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference (GlobeNewswire) - "Foghorn® Therapeutics...announced that...pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference....The Company will present data from its selective EP300 program, including in vitro selective degradation and antiproliferation in AR+ prostate and DLBCL cell lines....In addition, the Company will present results from next-generation-sequencing (NGS) analyses exploring the mechanism by which degradation of BRD9 may lead to proliferation defects in synovial sarcoma, as well as results from in vitro and in vivo studies demonstrating the anti-tumor efficacy of FHD-609, a BRD9 degrader, in a sub-type of AML."

Preclinical • Acute Myelogenous Leukemia • Diffuse Large B Cell Lymphoma • Prostate Cancer • Synovial Sarcoma